{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:40:58Z","timestamp":1777394458024,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,3,21]]},"DOI":"10.3233\/jad-160758","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T11:51:40Z","timestamp":1488282700000},"page":"387-393","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Risperidone and Galantamine Treatment on Alzheimer\u2019s Disease Biomarker Levels in Cerebrospinal Fluid"],"prefix":"10.1177","volume":"57","author":[{"given":"Victor","family":"Bloniecki","sequence":"first","affiliation":[{"name":"Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden"},{"name":"Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden"},{"name":"Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad","family":"Falahati","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Karolinska Institute, Caring Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Freund-Levi","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden"},{"name":"Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-160758_ref1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019sdisease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-160758_ref2","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1016\/j.jalz.2011.05.1237","article-title":"Neuropsychiatric symptoms as the main determinant of caregiver burden in Alzheimer\u2019s disease","volume":"7","author":"Cerveira","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-160758_ref3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00401-011-0821-3","article-title":"Clinicopathological correlates of behavioral and psychological symptoms of dementia","volume":"122","author":"Casanova","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-160758_ref4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3233\/JAD-140309","article-title":"Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"41","author":"Vermeiren","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160758_ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"Cerejeira","year":"2012","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-160758_ref6","doi-asserted-by":"crossref","first-page":"927804","DOI":"10.1155\/2014\/927804","article-title":"Behavioral and psychological symptoms in Alzheimer\u2019s disease","volume":"2014","author":"Li","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.3233\/JAD-160758_ref7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3233\/JAD-150181","article-title":"Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people","volume":"49","author":"Bensamoun","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160758_ref8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-160758_ref9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/npp.2013.154","article-title":"Biomarkers in amyloid-beta immunotherapy trials in Alzheimer\u2019s disease","volume":"39","author":"Blennow","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JAD-160758_ref10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-beta 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s disease: Validation of two novel assays","volume":"43","author":"Lewczuk","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160758_ref11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000363500","article-title":"Agitation in dementia: Relation to core cerebrospinal fluid biomarker levels","volume":"4","author":"Bloniecki","year":"2014","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.3233\/JAD-160758_ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","article-title":"Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-160758_ref13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jagp.2013.05.005","article-title":"Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: An open randomized trial","volume":"22","author":"Freund-Levi","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-160758_ref14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-160758_ref15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence","volume":"293","author":"Sink","year":"2005","journal-title":"JAMA"},{"key":"10.3233\/JAD-160758_ref16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/gps.1378","article-title":"Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies","volume":"20","author":"Ballard","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-160758_ref17","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1212\/01.wnl.0000261920.03297.64","article-title":"Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies","volume":"68","author":"Ballard","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JAD-160758_ref18","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.3233\/JAD-160758_ref19","volume-title":"Diagnostic and Statistical Manual of Mental Disorders IV","author":"American Psychiatric Association","year":"1995"},{"key":"10.3233\/JAD-160758_ref20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-160758_ref21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1532-5415.1986.tb04302.x","article-title":"Agitated behaviors in the elderly. I. A conceptual review","volume":"34","author":"Cohen-Mansfield","year":"1986","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-160758_ref22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol Chem Neuropathol"},{"key":"10.3233\/JAD-160758_ref23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","article-title":"Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization","volume":"285","author":"Vanmechelen","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-160758_ref24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","article-title":"Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease","volume":"56","author":"Andreasen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-160758_ref25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2007.03.064","article-title":"Longitudinal stability of CSF biomarkers in Alzheimer\u2019s disease","volume":"419","author":"Blennow","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-160758_ref26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: Randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"key":"10.3233\/JAD-160758_ref27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer\u2019s disease: Outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-160758_ref28","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.4161\/15548627.2014.984270","article-title":"Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine","volume":"10","author":"Vucicevic","year":"2014","journal-title":"Autophagy"},{"key":"10.3233\/JAD-160758_ref29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: A follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-160758_ref30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JAD-2007-12307","article-title":"Intra-individual stability of CSF biomarkers for Alzheimer\u2019s disease over two years","volume":"12","author":"Zetterberg","year":"2007","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160758_ref31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-2012-110029","article-title":"Longitudinal stability of cerebrospinal fluid biomarker levels: Fulfilled requirement for pharmacodynamic markers in Alzheimer\u2019s disease","volume":"33","author":"Le Bastard","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160758_ref32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-9-22","article-title":"Identification of longitudinally dynamic biomarkers in Alzheimer\u2019s disease cerebrospinal fluid by targeted proteomics","volume":"9","author":"Wildsmith","year":"2014","journal-title":"Mol Neurodegener"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-160758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:18Z","timestamp":1777370598000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-160758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":32,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-160758","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]}}}